|
1
|
Kavaliauskas P, Grybaitė B, Sapijanskaite-Banevič B, Anusevičius K, Jonuškienė I, Stankevičienė R, Petraitienė R, Petraitis V, Grigalevičiūtė R, Meškinytė E, Stankevičius R, Mickevičius V. Identification of 3-((4-Hydroxyphenyl)amino)propanoic Acid Derivatives as Anticancer Candidates with Promising Antioxidant Properties. Molecules 2024; 29:3125. [PMID: 38999077 PMCID: PMC11243380 DOI: 10.3390/molecules29133125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2024] [Revised: 06/27/2024] [Accepted: 06/28/2024] [Indexed: 07/14/2024] Open
Abstract
Various cancer-associated morbidities remain a growing global health challenge, resulting in a significant burden on healthcare systems worldwide due to high mortality rates and a frequent lack of novel therapeutic options for advanced and localized disease. Reactive oxygen species (ROS) play an important role in cancer pathogenesis and response to chemotherapeutics; therefore, it is crucial to develop novel compounds with both antioxidant and anticancer activity. In this study, a series of previously reported 3-((4-hydroxyphenyl)amino)propanoic acid derivatives (compounds 1-36) were evaluated for their anticancer and antioxidant activities. Compounds 12, 20-22, and 29 were able to reduce A549 cell viability by 50% and suppress A549 cell migration in vitro. These compounds also showed favorable cytotoxicity properties towards noncancerous Vero cells. The most promising candidate, compound 20, exhibited potent antioxidant properties in the DPPH radical scavenging assay. These results demonstrate that 3-((4-hydroxyphenyl)amino)propanoic acid could be further explored as an attractive scaffold for the development of novel anticancer and antioxidant candidates.
Collapse
Affiliation(s)
- Povilas Kavaliauskas
- Department of Organic Chemistry, Kaunas University of Technology, LT-50254 Kaunas, Lithuania; (B.G.); (B.S.-B.); (K.A.); (I.J.); (R.S.); (V.M.)
- Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, NY 10065, USA; (R.P.); (V.P.)
- Institute of Infectious Diseases and Pathogenic Microbiology, LT-59116 Prienai, Lithuania
- Biological Research Center, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania;
| | - Birutė Grybaitė
- Department of Organic Chemistry, Kaunas University of Technology, LT-50254 Kaunas, Lithuania; (B.G.); (B.S.-B.); (K.A.); (I.J.); (R.S.); (V.M.)
| | - Birute Sapijanskaite-Banevič
- Department of Organic Chemistry, Kaunas University of Technology, LT-50254 Kaunas, Lithuania; (B.G.); (B.S.-B.); (K.A.); (I.J.); (R.S.); (V.M.)
| | - Kazimieras Anusevičius
- Department of Organic Chemistry, Kaunas University of Technology, LT-50254 Kaunas, Lithuania; (B.G.); (B.S.-B.); (K.A.); (I.J.); (R.S.); (V.M.)
| | - Ilona Jonuškienė
- Department of Organic Chemistry, Kaunas University of Technology, LT-50254 Kaunas, Lithuania; (B.G.); (B.S.-B.); (K.A.); (I.J.); (R.S.); (V.M.)
| | - Rima Stankevičienė
- Department of Organic Chemistry, Kaunas University of Technology, LT-50254 Kaunas, Lithuania; (B.G.); (B.S.-B.); (K.A.); (I.J.); (R.S.); (V.M.)
| | - Rūta Petraitienė
- Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, NY 10065, USA; (R.P.); (V.P.)
- Institute of Infectious Diseases and Pathogenic Microbiology, LT-59116 Prienai, Lithuania
| | - Vidmantas Petraitis
- Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, NY 10065, USA; (R.P.); (V.P.)
- Institute of Infectious Diseases and Pathogenic Microbiology, LT-59116 Prienai, Lithuania
- Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA
| | - Ramunė Grigalevičiūtė
- Biological Research Center, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania;
- Department of Animal Nutrition, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania;
| | - Edita Meškinytė
- Center of Animal Production Research and Innovation, Agriculture Academy, Vytautas Magnus University, LT-44248 Kaunas, Lithuania;
| | - Rolandas Stankevičius
- Department of Animal Nutrition, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania;
| | - Vytautas Mickevičius
- Department of Organic Chemistry, Kaunas University of Technology, LT-50254 Kaunas, Lithuania; (B.G.); (B.S.-B.); (K.A.); (I.J.); (R.S.); (V.M.)
| |
Collapse
|
|
2
|
Mohamed FZ, Eid SA, Elghareb MS, Abas ASM. Molecular Docking and In Vivo Biological Studies of Sodium Salt of 3-(4-Methyl-2-oxo-2-H-quinoline-7-yloxy)-3-phenylacrylic Acid As Anticancer Agent. DOKL BIOCHEM BIOPHYS 2023; 512:300-318. [PMID: 38093135 DOI: 10.1134/s1607672923600203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Revised: 07/07/2023] [Accepted: 07/11/2023] [Indexed: 12/18/2023]
Abstract
Quinoline derivatives possess several therapeutic properties. Aim: studying the anticancer effect of 3-(4-methyl-2-oxo-2-H-quinoline-7-yloxy)-3-phenylacrylic acid's sodium solution on the Ehrlich ascites carcinoma (EAC). Median lethal dose (LD50) and dose response curve was determined for sodium salt solution of 3-(4-methyl-2-oxo-2-H-quinoline-7-yloxy)-3-phenylacrylic acid, then diving a group of one hundred Swiss albino mice, which are all females, into five groups: group 1: (negative control) where intraperitoneally injected with saline into mice for 10 successive days; group 2 (positive control), also namely (EAC-bearing group): where the EAC cells were intraperitoneally injected into mice (2.5 × 106 cells/mouse) only one time on the first day; group 3 which is defined as the (therapeutic group) where the Na+ salt of the synthetic compound was injected into the peritoneum of the mice (2.5 mg/kg) the very first day after the injection of the EAC, then the compound was injected every two days for a period of 10 days; group 4 which is the (preventive group) where the sodium salt of the synthetic compound (2.5 mg/kg) was injected in the peritoneum of the mice the day before the injection of the EAC, then the compound was successively injected every day for a period of ten days; and group 5 which is the (drug group) in which mice were repeatedly injected) in their peritoneum with the sodium salt of the synthetic compound (2.5 mg/kg on a daily basis over a period of ten days. On the eleventh day of the trial, EAC cells were harvested from each mouse in a heparinized saline, in addition to blood samples, liver and kidney tissues which are also collected. Molecular docking showed that compound's sodium salt was docked into (PDB: 2R7G) and (PDB: 2R3I), which are the retinoblastoma protein receptor and the cyclin D-1 receptor respectively. Compared to those in the positive control group, mice in both the therapeutic and preventive groups, has shown a significant decrease in MDA, cyclin D-1 levels in the tissues of both liver and kidney tissues, in addition to the serum ALT, AST, CK-MB, and LDH activities, and the serum urea and creatinine concentration. However, mice in the formerly mentioned groups, both therapeutic and preventive groups, have shown an increase in the serum albumin, total protein, retinoblastoma protein in both liver and kidney tissues as well as the total antioxidant capacity, when compared to mice in the positive control group. It is worth mentioning that histopathological findings have confirmed that. Sodium salt of 3-(4-methyl-2-oxo-2H-quinoline-7-yloxy)-3-phenylacrylic acid showed potential in vivo anticancer and antioxidant effects against Ehrlich ascites carcinoma cells; (EAC cells).
Collapse
Affiliation(s)
- Faten Z Mohamed
- Chemistry Department (Biochemistry Branch), Faculty of Science, Zagazig University, Zagazig, Egypt
| | - Sarah A Eid
- Chemistry Department, Faculty of Science, Port Said University, Port Said, Egypt
| | - Mohamed S Elghareb
- Chemistry Department, Faculty of Science, Port Said University, Port Said, Egypt
| | - Al-Shimaa M Abas
- Chemistry Department (Biochemistry Branch), Faculty of Science, Zagazig University, Zagazig, Egypt.
| |
Collapse
|